Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

INSIDE INFORMATION ANNOUNCEMENT NOTIFICATION LETTER FROM THE CHINA SECURITIES REGULATORY COMMISSION REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company announces that the Company has recently received the official notification letter on its application for H share full circulation (the "**Notification**") from the China Securities Regulatory Commission (the "**CSRC**"), pursuant to which the Company's filing with the CSRC regarding the conversion of a total of 5,989,798 unlisted shares held by two shareholders of the Company into 5,989,798 H shares on a one-to-one basis has been completed. Upon completion of such conversion and listing approval granted by the Stock Exchange, such 5,989,798 H shares will be listed and traded on the Main Board of the Stock Exchange. The Notification shall be valid for 12 months from the date of approval by the CSRC. Details of names of shareholders and number of shares for conversion under the H share full circulation plan are as follows:

Name of shareholders	Number of unlisted shares to be converted into H shares	Approximate percentage of the Company's total issued share capital as at the date of this announcement*Note*
Shanghai Runkun Tianlu Enterprise Management Center (LLP)	589,806	0.0572%
Shenzhen Xinlong Investment LLP	5,399,992	0.5236%
TOTAL	**5,989,798**	**0.5808%**

Note: As at the date of this announcement, the Company has issued a total number of 1,031,330,331 shares, comprising 6,599,543 unlisted shares and 1,024,730,788 H shares.

As at the date of this announcement, details of the Company's implementation plan of the H share full circulation and the conversion and listing have not been finalised, and the completion of the H share full circulation and the conversion and listing is subject to the fulfillment of other relevant procedural requirements by the Stock Exchange and other relevant domestic and overseas regulatory authorities. The Company will make further announcement(s) on the progress of the H share full circulation and the conversion and listing in compliance with the Listing Rules as and when appropriate.

The completion of the H share full circulation and the conversion and listing is subject to other relevant procedures as required by the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 4 February 2026

As at the date of this announcement, the executive directors are Dr. Chao He and Mr. Yu Liu, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.